Systems and methods for controlling inflammatory response

US9314555B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9314555-B2
Application numberUS-201213550787-A
CountryUS
Kind codeB2
Filing dateJul 17, 2012
Priority dateSep 18, 2008
Publication dateApr 19, 2016
Grant dateApr 19, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method and system for controlling inflammatory response at an internal tissue site of a patient utilizes a reduced-pressure treatment device. Controlling the inflammatory response may be accomplished in a number of ways that involve treating the inflammatory milieu. Treating the inflammatory milieu may include removing or moderating pro-inflammatory stimuli, e.g., fluids, enhancing perfusion of the tissue at or near the internal tissue site, or providing reduced-pressure therapy. The reduced-pressure treatment device is placed at or near the internal tissue site and is fluidly coupled to an external reduced-pressure source. The reduced-pressure treatment device provides reduced pressure proximate the tissue site and treats the inflammatory milieu. The reduced-pressure treatment device for controlling inflammatory response may be a minimally-invasive treatment device.

First claim

Opening claim text (preview).

We claim: 1. A system for controlling inflammatory response at an internal tissue site of a patient, the system comprising: a reduced-pressure treatment device configured for deploying in an abdominal cavity interior to the patient's peritoneum proximate the internal tissue site, the reduced-pressure treatment device consisting essentially of a first leg manifold member and a second leg manifold member fluidly coupled to the first leg manifold member, and an encapsulating envelope formed with fenestrations and enveloping the first leg manifold member and the second leg manifold member; an external reduced-pressure source for supplying reduced pressure to the reduced-pressure treatment device; a reduced-pressure delivery conduit for fluidly coupling the reduced-pressure source and the reduced-pressure treatment device; and wherein the reduced-pressure source, reduced-pressure delivery conduit, and reduced-pressure treatment device are operable to provide reduced pressure to the internal tissue site to moderate pro-inflammatory stimuli in order to control systemic inflammatory response throughout the patient's body; the first leg manifold member and the second leg manifold member intersect to form a central connection site; and the encapsulating envelope forms an exterior layer over the first leg manifold member, the second leg manifold member, and the central connection site; and the first leg manifold member and second leg manifold member form two obtuse angles and two acute angles. 2. The system for controlling inflammatory response of claim 1 , wherein the first leg manifold member and the second leg manifold member have an aspect ratio greater than 3.0. 3. The system for controlling inflammatory response of claim 2 , wherein the aspect ratio is greater than 4.0. 4. The system for controlling inflammatory response of claim 2 , wherein the aspect ratio is greater than 5.0. 5. The system of claim 1 , further comprising a sealing member adapted to be placed over the reduced-pressure treatment device and the internal tissue site. 6. The system of claim 5 , wherein at least a portion of the sealing member is further adapted to form at least a portion of the encapsulating envelope. 7. The system of claim 5 , further comprising a manifold adapted to be positioned between the sealing member and the reduced-pressure treatment device and to distribute reduced pressure to the reduced-pressure treatment device. 8. The system of claim 1 , wherein the first leg manifold member and the second leg manifold member each comprise at least two leg modules and a manipulation zone positioned between the leg modules. 9. The system of claim 1 , further comprising a connection member coupled to the first encapsulated leg member and the second encapsulated leg member.

Assignees

Inventors

Classifications

  • Abdomen bandages or bandaging garments · CPC title

  • Implant devices for drainage of body fluids from one part of the body to another (intraocular A61F9/00781; middle ear A61F11/202) · CPC title

  • with fluid retention members · CPC title

  • Drainage appliance for wounds or the like {, i.e. wound drains, implanted drains} ({negative pressure wound therapy devices A61M1/90;} implements for holding wound open A61B17/02 {; middle ear drainage A61F11/202}) · CPC title

  • Abdominal cavity · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9314555B2 cover?
A method and system for controlling inflammatory response at an internal tissue site of a patient utilizes a reduced-pressure treatment device. Controlling the inflammatory response may be accomplished in a number of ways that involve treating the inflammatory milieu. Treating the inflammatory milieu may include removing or moderating pro-inflammatory stimuli, e.g., fluids, enhancing perfusion …
Who is the assignee on this patent?
Stevenson Eric, Norbury Kenneth, Mormino Richard Paul, and 2 more
What technology area does this patent fall under?
Primary CPC classification A61M1/915. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).